| Shawna Schmidt, CRNA | |
|
2460 Curtis Ellis Dr, Rocky Mount, NC 27804-2298 | |
| (252) 962-8000 | |
| Not Available |
| Full Name | Shawna Schmidt |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 4 Years |
| Location | 2460 Curtis Ellis Dr, Rocky Mount, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619580925 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 28077 (South Carolina) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | 293712 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kearney Regional Medical Center | Kearney, NE | Hospital |
| Prisma Health Baptist | Columbia, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bryan Hospital Kearney | 5991195547 | 91 |
| Prisma Health University Medical Group | 8325950983 | 2201 |
News Archive
A research team led by a scientist at the University of California, Riverside, has found that brains treated with certain drugs within a few days of an injury have a dramatically reduced risk of developing epilepsy later in life.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today summarized new data highlighting the progress of OncoMed's pipeline of anti-cancer biologics presented this week in an oral presentation and five posters at the Annual Meeting of the American Association of Cancer Research in Washington, DC.
A new strategy for treating brain tumors may extend or save the lives of patients diagnosed with one of the deadliest forms of cancer, according to a study from UT Southwestern Medical Center.
The A143T variant of the GLA gene is associated with an increased risk of Fabry cardiomyopathy, according to a new study.
› Verified 9 days ago
| Entity Name | Northstar Anesthesia Of Nebraska Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578187670 PECOS PAC ID: 2264857135 Enrollment ID: O20200810001420 |
News Archive
A research team led by a scientist at the University of California, Riverside, has found that brains treated with certain drugs within a few days of an injury have a dramatically reduced risk of developing epilepsy later in life.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today summarized new data highlighting the progress of OncoMed's pipeline of anti-cancer biologics presented this week in an oral presentation and five posters at the Annual Meeting of the American Association of Cancer Research in Washington, DC.
A new strategy for treating brain tumors may extend or save the lives of patients diagnosed with one of the deadliest forms of cancer, according to a study from UT Southwestern Medical Center.
The A143T variant of the GLA gene is associated with an increased risk of Fabry cardiomyopathy, according to a new study.
› Verified 9 days ago
| Entity Name | Bryan Hospital Kearney |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033875380 PECOS PAC ID: 5991195547 Enrollment ID: O20211214002678 |
News Archive
A research team led by a scientist at the University of California, Riverside, has found that brains treated with certain drugs within a few days of an injury have a dramatically reduced risk of developing epilepsy later in life.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today summarized new data highlighting the progress of OncoMed's pipeline of anti-cancer biologics presented this week in an oral presentation and five posters at the Annual Meeting of the American Association of Cancer Research in Washington, DC.
A new strategy for treating brain tumors may extend or save the lives of patients diagnosed with one of the deadliest forms of cancer, according to a study from UT Southwestern Medical Center.
The A143T variant of the GLA gene is associated with an increased risk of Fabry cardiomyopathy, according to a new study.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shawna Schmidt, CRNA 2460 Curtis Ellis Dr, Rocky Mount, NC 27804-2298 Ph: () - | Shawna Schmidt, CRNA 2460 Curtis Ellis Dr, Rocky Mount, NC 27804-2298 Ph: (252) 962-8000 |
News Archive
A research team led by a scientist at the University of California, Riverside, has found that brains treated with certain drugs within a few days of an injury have a dramatically reduced risk of developing epilepsy later in life.
PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today summarized new data highlighting the progress of OncoMed's pipeline of anti-cancer biologics presented this week in an oral presentation and five posters at the Annual Meeting of the American Association of Cancer Research in Washington, DC.
A new strategy for treating brain tumors may extend or save the lives of patients diagnosed with one of the deadliest forms of cancer, according to a study from UT Southwestern Medical Center.
The A143T variant of the GLA gene is associated with an increased risk of Fabry cardiomyopathy, according to a new study.
› Verified 9 days ago
Ms. Monica Lynn Seaman, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2460 Curtis Ellis Dr, Rocky Mount, NC 27804 Phone: 252-443-8030 Fax: 252-443-8397 | |
Mr. Robert Hollowell Reed, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 2460 Curtis Ellis Dr, Rocky Mount, NC 27804 Phone: 252-443-8030 Fax: 252-443-8397 | |
Mr. Nelson Wade White, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 2460 Curtis Ellis Dr, Rocky Mount, NC 27804 Phone: 252-443-8030 Fax: 252-443-8397 | |
Lindsey Tyndall Liles, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2460 Curtis Ellis Dr, Rocky Mount, NC 27804 Phone: 252-962-8679 | |
Ellery Swain, DNP, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 2460 Curtis Ellis Dr, Rocky Mount, NC 27804 Phone: 919-208-8824 | |
Elizabeth Morgan Lamberson, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2460 Curtis Ellis Dr, Rocky Mount, NC 27804 Phone: 252-962-6633 | |
Bianca Sink, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2460 Curtis Ellis Dr, Rocky Mount, NC 27804 Phone: 252-962-8199 |